CCL5 and breast neoplasm: Mechanistic studies in in vitro and in vivo ADCC models indicate the importance of NK cells for the initial production of CCL5/IFN-ɣ, subsequently resulting in CXCL9/10 production by bystander breast tumor cells, during anti-HER2 antibody treatment.